Allogene holder plans sale of 26269 shares

Allogene Therapeutics, Inc. has a planned sale of 26269 shares of common stock, as disclosed in a Form 144 notice.

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. has a planned sale of 26269 shares of common stock, as disclosed in a Form 144 notice. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/21/2026 and an aggregate market value of 40929.05.

The securities were acquired on 01/20/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. Shares outstanding were 224730144 at the time of the notice; this is a baseline figure, not the amount being sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ALLO disclose?

The Form 144 filing for Allogene Therapeutics, Inc. (ALLO) discloses a planned sale of 26269 shares of common stock on the NASDAQ through Morgan Stanley Smith Barney LLC, with an aggregate market value of 40929.05 and an approximate sale date of 01/21/2026.

How many Allogene Therapeutics (ALLO) shares are planned to be sold and on which exchange?

The notice covers a planned sale of 26269 shares of Allogene Therapeutics common stock, to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC.

What is the reported market value of the ALLO shares in this Form 144?

The 26269 Allogene Therapeutics shares covered by the Form 144 have an aggregate market value of 40929.05 as stated in the filing.

How were the Allogene Therapeutics (ALLO) shares being sold acquired?

The common stock was acquired on 01/20/2026 through the vesting of a restricted stock unit award, granted as part of Allogene Therapeutics, Inc.’s equity compensation plan.

When is the approximate sale date for the ALLO shares under this Form 144?

The filing lists an approximate sale date of 01/21/2026 for the 26269 shares of Allogene Therapeutics common stock.

How many Allogene Therapeutics (ALLO) shares are outstanding according to this notice?

The Form 144 states that 224730144 shares of Allogene Therapeutics common stock were outstanding at the time of the notice, which serves as a baseline figure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 07:53 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001851044
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Roberts Zachary
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26269	40929.05	224730144	01/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/20/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.			26269	01/20/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Zachary Roberts
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)